The filing mostly confirms previously known milestones, rather than creating a new surprise. The AbbVie deal remains a $135.11-per-share cash acquisition targeted for the third quarter, while the positive APEX Part B data and planned Phase 3 start were already announced in May and June (Corporate Updates; Pipeline Progress). No new published earnings consensus is provided here, so the financial read is versus the prior-year quarter rather than a quantified beat or miss.
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| R&D expense | $67.3 million (Statements of Operations) | $55.7 million (Statements of Operations) | +20.8% |
| G&A expense | $24.3 million (Statements of Operations) | $17.5 million (Statements of Operations) | +39.4% |
| Merger transaction costs | $4.4 million (Statements of Operations) | — | New |
| Net loss | $85.9 million (Statements of Operations) | $66.1 million (Statements of Operations) | Loss widened by $19.8 million |
| Cash, marketable securities and long-term marketable securities | $1.294 billion (Condensed Consolidated Balance Sheets) | $621.2 million, as reported by the company (Cash Position) | Higher liquidity |
The quarter is financially weaker on an operating basis, but the deterioration is expected for a clinical-stage biotech moving toward late-stage trials. R&D increased to $67.3 million as zumilokibart development advanced, while G&A rose to $24.3 million and the company recorded $4.4 million of merger costs (Second Quarter 2026 Financial Results; Statements of Operations). The wider $85.9 million net loss is therefore not an unexpected pipeline setback, but it does show that spending is accelerating.
Funding is the strongest financial takeaway. Securities and cash totaled approximately $1.294 billion at June 30, 2026, and the balance sheet also reflects a $99.2 million revenue-share liability (Condensed Consolidated Balance Sheets). Combined with the previously announced Blackstone collaboration for up to $1.3 billion of non-dilutive capital, the filing supports a well-funded path into Phase 3 without an immediate need for equity financing, although the Blackstone amount is a maximum commitment rather than cash already received (Corporate Updates).
The pipeline update is constructive but not new enough to qualify as a fresh earnings surprise. Mid-dose zumilokibart produced a 65.9% EASI-75 response, with a 41.9% placebo-adjusted benefit, and the company plans to begin Phase 3 in atopic dermatitis this year (Pipeline Progress). EoE testing is planned for the second half of 2026, asthma development for the first half of 2027, and interim combination-program data are expected in the second half of 2026 (Pipeline Progress). The net read is therefore mixed: execution and liquidity remain intact, but the release largely reiterates the market's existing acquisition and development picture while reporting higher costs and a larger loss.
Read the original 8-K on SEC EDGAR ↗